Indiana devicemakers are among a throng of biotech industry players that has taken up with the state to launch an estimated $360 million public-private research institute to further Indiana's already-thriving biotech industry.
Sequenom has inked a deal with France's Laboratoire Cerba to expand the reach of the company's MaterniT21 Plus test, designed to non-invasively detect chromosomal abnormalities.
GlaxoSmithKline's latest attempt to enlist the academic community in its translational research efforts has won a chilly reception from the upper echelon of UCLA.
In an effort to widen its search for new small-molecule drug candidates, Pfizer is extending its biologics partnership with the University of California, building on the company's already robust Centers for Therapeutic Innovation program.
Chapel Hill, NC-based Cempra has won a $58 million contract from BARDA to develop its lead, late-stage antibiotic for bioterror threats aimed at a pediatric population.
Illumina has partnered with Hamilton Robotics to develop automated sample preparation for the company's next-generation sequencing platforms.
Just a few months after Amgen execs lamented a big Asian gap in their global strategy, the Big Biotech company has joined hands with Astellas to set up a new joint venture in Japan. Amgen is contributing 5 experimental-stage programs to the JV, including their late-stage anti-PCSK9 program for the cholesterol drug AMG-145.
Luminex has inked a long-term agreement with Merck KGaA's life sciences business, tasking the German company with providing assays for Luminex's research technology.
German CRO Cenix BioScience has agreed to handle preclinical work for Debiopharm's oncology pipeline, using its high-content assays to identify biomarkers.
Diagnostics outfit Corgenix has paired up with Eli Lilly to develop tests for the drugmaker's oncology pipeline, a step forward in the company's efforts to expand its contract services business.